Argus analyst Jasper Hellweg raised the firm’s price target on AstraZeneca to $85 from $75 and keeps a Buy rating on the shares. The analyst notes that the company has received a range of new product approvals in recent months, including for multiple oncology drugs and treatments for asthma, autoimmune disease, and chronic heart failure. Argus further states that AstraZeneca has shown impressive growth in its existing portfolio, with a 24% increase in constant-currency product sales in 2022 and significantly higher margins.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AZN:
- 3 Best Stocks to Buy Now, 4/14/2023, According to Top Analysts
- Fusion Pharmaceuticals receives IND clearance for Alpha therapy FPI-2068
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- AstraZeneca price target lowered to 11,900 GBp from 12,700 GBp at Guggenheim
- AstraZeneca updates arrangements with Sobi, Sanofi for nirsevimab in U.S.
